[{"data":1,"prerenderedAt":164},["ShallowReactive",2],{"drug-fremanezumab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":66,"warnings":76,"renal":84,"monitoring":85,"interactions":86,"review":87,"examples":90,"atc":100,"iran":102,"usApproval":109,"links":115,"populations":130},"fremanezumab",1,{"fa":7,"en":8},"فرمانزوماب","Fremanezumab","nervous-system",{"fa":11,"en":12},"آنتی‌بادی ضد CGRP","Anti-CGRP monoclonal antibody",[14],{"name":15,"market":16},"Ajovy","US",[18,19,7],"ajovy","آجووی",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"pfs-225","injection","sc","225 mg\u002F1.5 mL prefilled syringe or autoinjector",{"amount":27,"unit":28,"perVolumeMl":29},225,"mg",1.5,[16],[32],{"source":33,"section":34},"fda-ajovy","3",[36,53],{"id":37,"disease":38,"label":39,"population":42,"type":47,"unit":28,"dose":48,"refs":49,"durationDays":52},"m","migraine-prophylaxis",{"fa":40,"en":41},"پیشگیری میگرن — ۲۲۵ mg زیرجلدی ماهانه (بزرگسال؛ کودک ۶ تا ۱۷ سال ≥۴۵ kg برای اپیزودیک)","Migraine prevention — 225 mg SC monthly (adults; children 6–17 y ≥45 kg for episodic)",{"minAge":43,"minWeightKg":46},{"value":44,"unit":45},6,"year",45,"fixed",{"perDose":27,"dosesPerDay":5},[50],{"source":33,"section":51},"2.1",{"min":5,"max":5},{"id":54,"disease":38,"label":55,"population":58,"type":47,"unit":28,"dose":61,"refs":63,"durationDays":65},"q",{"fa":56,"en":57},"پیشگیری میگرن بزرگسال — ۶۷۵ mg هر ۳ ماه (سه تزریق پشت سر هم ۲۲۵ mg)","Migraine prevention, adults — 675 mg every 3 months (three consecutive 225 mg injections)",{"minAge":59},{"value":60,"unit":45},18,{"perDose":62,"dosesPerDay":5},675,[64],{"source":33,"section":51},{"min":5,"max":5},[67],{"id":68,"severity":69,"text":70,"refs":73},"hyper","block",{"fa":71,"en":72},"حساسیت جدی به فرمانزوماب (آنافیلاکسی، آنژیوادم).","Serious hypersensitivity to fremanezumab (anaphylaxis, angioedema).",[74],{"source":33,"section":75},"4",[77],{"text":78,"refs":81},{"fa":79,"en":80},"واکنش حساسیتی؛ یبوست با عوارض جدی؛ فشار خون بالا؛ پدیده رینود.","Hypersensitivity; constipation with serious complications; hypertension; Raynaud phenomenon.",[82],{"source":33,"section":83},"5",[],[],[],{"status":88,"reviewer":89,"date":89},"unverified",null,[91,96],{"regimen":37,"formulation":22,"input":92,"expect":95},{"ageYears":93,"weightKg":94},35,65,{"perDose":27,"mlPerDose":29},{"regimen":54,"formulation":22,"input":97,"expect":98},{"ageYears":93,"weightKg":94},{"perDose":62,"mlPerDose":99},4.5,[101],"N02CD03",{"status":103,"refs":104},"not-found",[105],{"source":106,"section":107,"url":108},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Fremanezumab",{"kind":110,"refs":111,"id":114},"BLA",[112],{"source":33,"section":113},"SPL approval \u002F marketing category","BLA761089",[116,119,123,127],{"kind":117,"url":118,"label":114},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=761089",{"kind":120,"url":121,"label":122},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=98e344ea-5916-4947-b6f2-4a76ccc04b6b","FDA Ajovy",{"kind":124,"url":125,"label":126},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa618053.html","Fremanezumab-vfrm Injection",{"kind":128,"url":129,"label":101},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N02CD03",{"pregnancy":131,"lactation":140,"pediatric":148,"geriatric":156},{"level":132,"text":133,"quote":136,"refs":137},"caution",{"fa":134,"en":135},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women.",[138],{"source":33,"section":139},"8.1",{"level":132,"text":141,"quote":144,"refs":145},{"fa":142,"en":143},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of fremanezumab-vfrm in human milk, the effects on the breastfed infant, or the effects on milk production.",[146],{"source":33,"section":147},"8.2",{"level":132,"text":149,"quote":152,"refs":153},{"fa":150,"en":151},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Episodic Migraine The safety and effectiveness of AJOVY have been established in an adequate and well-controlled study for the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more (Study 3).",[154],{"source":33,"section":155},"8.4",{"level":132,"text":157,"quote":160,"refs":161},{"fa":158,"en":159},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical studies of AJOVY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.",[162],{"source":33,"section":163},"8.5",1792191545858]